MoriVid contains the active substance hydroxychloroquine sulfate. It works by reducing inflammation in people with autoimmune diseases (the immune system attacks healthy cells in the body).


– Prevention and treatment of malaria;
– Treatment of rheumatoid arthritis;
– Treatment of discoid and systemic lupus erythematosus;
– Dermatological conditions caused by sunlight.

Paediatric population (≥ 6 years and ≥ 31 kg):
– Treatment of juvenile idiopathic arthritis (in combination with other therapies);
– Treatment of discoid and systemic lupus erythematosus.

Chloroquine-resistant P. falciparum and increasingly chloroquine-resistant P. vivax are found in many areas, which limits the applicability of hydroxychloroquine in these areas. Official guidelines and local information on the development of resistance to antimalarial agents should be followed.

Subject to medical prescription.

Concentration and pharmaceutical form: 200 mg film-coated tablets